Sunesis Pharmaceuticals, Inc. (SNSS) News

Sunesis Pharmaceuticals, Inc. (SNSS): $18.62

3.64 (+24.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SNSS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 487

in industry

Filter SNSS News Items

SNSS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SNSS News Highlights

  • SNSS's 30 day story count now stands at 4.
  • Over the past 8 days, the trend for SNSS's stories per day has been choppy and unclear. It has oscillated between 2 and 2.
  • The most mentioned tickers in articles about SNSS are AG, BFRA and CELC.

Latest SNSS News From Around the Web

Below are the latest news stories about Sunesis Pharmaceuticals Inc that investors may wish to consider to help them evaluate SNSS as an investment opportunity.

Sunesis Pharmaceuticals, Owens & Minor leads healthcare gainers; Rafael, Constellation Pharmaceuticals among major losers

Gainers: Sunesis Pharmaceuticals (SNSS) +38%, Owens & Minor (OMI) +32%, Salarius Pharmaceuticals (SLRX) +20%, Poseida Therapeutics (PSTX) +20%, PRA Health Sciences (PRAH) +19%.Losers: Rafael (RFL) -12%, Constellation Pharmaceuticals (CNST) -12%, Biofrontera AG (BFRA) -10%, Celcuity (CELC) -9%, Tactile Systems Technology (TCMD) -7%....

Seeking Alpha | February 24, 2021

Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS"). The combined, publicly traded company will focus on the advancement and expansion of Viracta's clinical stage pipeline, including Viracta's lead program for the treatment of Epstein-Barr virus (EBV)-positive lymphoma. Shares of the combined company, which is operating under the name Viracta Therapeutics, Inc., will commence trading on the Nasdaq Global Select Market under the ticker symbol "VIRX" on February 25, 2021.

Yahoo | February 24, 2021

Sunesis Pharma Climbs After Viracta Poised To Nab US Patent For Nanatinostat/Valganciclovir Regime

Sunesis Pharmaceuticals Inc (NASDAQ: SNSS) merger partner, Viracta Therapeutics Inc announces that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/924,082, titled "Methods of Treating Virally Associated Cancers with Histone Deacetylase Inhibitors," related to the use of Viracta's oral combination product candidate of nanatinostat and valganciclovir. The allowed claims cover the anticipated dose regimen to be advanced in the planned global registration trial to treat Epstein-Barr virus (EBV)-associated lymphoma and other lymphoproliferative disorders. Upon its grant, the resulting patent will provide protection into at least 2040. In November last year, Sunesis Pharmaceuticals announced to merge with Viracta Therapeutics in an a...

Yahoo | February 16, 2021

Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/924,082. The allowed application, titled "Methods of Treating Virally Associated Cancers with Histone Deacetylase Inhibitors," describes the use of Viracta's all-oral combination product candidate of nanatinostat, the Company's proprietary investigational drug, and valganciclovir. The allowed claims cover the anticipated dose regimen to be advanced in the planned global registration trial for the treatment of Epstein-Barr virus (EBV)-associated lymphoma and other lymphoproliferative disorders. Upon its grant, the resulting patent will prov...

Yahoo | February 16, 2021

MERGER INVESTIGATION: Halper Sadeh LLP Investigates CPAH, HMSY, SNSS, EIDX; Shareholders Are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / January 8, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:CounterPath Corporation (NASDAQ:CPAH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Alianza, Inc. If you are a CounterPath shareholder, click here to learn more about your rights and options.

Yahoo | January 9, 2021

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of SNSS, LOAC, FBSS, and CPAH Mergers

WILMINGTON, Del., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: Sunesis Pharmaceuticals, Inc. (NASDAQ CM: SNSS) regarding possible breaches of fiduciary duties and other violations of law related to Sunesis’ agreement to merge with Viracta. Under the terms of the agreement, Sunesis will issue a number of shares of Sunesis common stock to shareholders of Viracta. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-sunesis-pharmaceuticals-inc.Longevity Acquisition Corporation (NASDAQ GS: LOAC) regarding possible breaches of fiduciary duties and other violations of law related to Longevity’s agreement to merge with 4D Pharma PLC. Under the terms of the agreement, Longevity’s shareholders will rec...

Yahoo | January 7, 2021

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - AKER, INFO, SNSS, WORK, WDR

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Yahoo | December 19, 2020

SHAREHOLDER ALERT: WeissLaw LLP Reminds NGA, FIII, and SNSS Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Yahoo | December 19, 2020

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of INFO, SNSS, INSU, and FBSS Mergers

WILMINGTON, Del., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: IHS Markit Ltd. (NYSE: INFO) regarding possible breaches of fiduciary duties and other violations of law related to IHS Markit’s agreement to be acquired by S&P Global Inc. Under the terms of the agreement, IHS Markit’s shareholders will receive 0.2838 shares of S&P common stock per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-ihs-markit-ltd.Sunesis Pharmaceuticals, Inc. (NASDAQ CM: SNSS) regarding possible breaches of fiduciary duties and other violations of law related to Sunesis’ agreement to merge with Viracta. Under the terms of the agreement, Sunesis will issue a number of shares of Sunesis common stock to shar...

Yahoo | December 17, 2020

INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate the Following Companies; Shareholders are Encouraged to Contact the Firm – SNSS, WORK, WDR, ANH

NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Viracta Therapeutics, Inc. Under the terms of the merger agreement, Viracta stockholders will receive shares of newly issued Sunesis common stock. Sunesis stockholders are expected to own approximately 14% of the combined company on a fully diluted basis. If you are a Sunesis shareholder, click here to learn more about your rights and options.Slack Technologies, Inc. (NYSE: WORK) concerning potential violations of the federal securities laws and/or breaches of fiducia...

Yahoo | December 12, 2020


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7399 seconds.